Tesamorelin is a synthetic peptide analog of growth-hormone-releasing hormone (GHRH), consisting of a 44–amino-acid sequence engineered with a trans-3-hexenoic acid modification at the N-terminus. This structural modification enhances stability and receptor affinity, making Tesamorelin a valuable compound for controlled laboratory research.
In preclinical and biochemical studies, Tesamorelin has been used to investigate growth-hormone–axis signaling, intracellular cAMP pathways, peptide–receptor binding behavior, and metabolic gene expression models. Researchers utilize Tesamorelin to study how GHRH analogs may influence adipocyte activity, protein transcription cascades, and neuroendocrine signaling within in-vitro and ex-vivo experimental systems.
Manufactured in the United States under strict cGMP-aligned processes, each batch undergoes independent third-party purity testing to ensure consistency, identity, and research-grade specifications.
Primary Research Areas:
- GHRH receptor binding and peptide–receptor signal transduction
- cAMP-linked intracellular growth hormone pathway modeling
- Adipocyte gene-expression mapping in vitro
- Neuroendocrine regulation and peptide stability studies
- Protein transcription and metabolic pathway analysis
- Preclinical models of visceral adiposity regulation
Tesamorelin Structure:
Molecular Formula: C223H370N72O69S2
Molecular Weight: 5195.908 g/mol
PubChem ID: 44147413
CAS Number: 901758-09-6
